Investors might want to bet on Catalent (CTLT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics ...

Catalent's location in Bloomington has about 2,400 employees, down hundreds of workers in just the past few years. It laid ...

Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strengths highlight Catalent's robust biologics segment and expansive global infrastructure. Weaknesses underscore the ...

Catalent Inc (CTLT) stock saw a decline, ending the day at $60.7 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.96. The stock opened at $60.6 and touched a low of $60.49 ...

The contract drug manufacturer was expected to file the report on Aug. 29. The company is awaiting the closing of the $16.5 ...

As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether the regulator may next target a deal that some experts say could make it easier for ...

On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.4 which represents a decrease of $-0.32 or -0.53% from the prior close of $60.72. The stock opened at $60.7 and touched a ...

Aug 30 (Reuters) - Catalent (CTLT.N), opens new tab said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".